In a report issued on June 15, Jason Kolbert from Dawson James maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $19.00. The company’s shares closed last Friday at $8.47, close to its 52-week low of $7.13.
According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -3.6% and a 34.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Citius Pharmaceuticals.
Currently, the analyst consensus on Anavex Life Sciences is a Strong Buy with an average price target of $34.00.
See the top stocks recommended by analysts >>
Anavex Life Sciences’ market cap is currently $655.7M and has a P/E ratio of -14.64.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Read More on AVXL:
- Dawson James Thinks Athersys’ Stock is Going to Recover
- Maxim Group Thinks Medivir AB’s Stock is Going to Recover
- KeyBanc Thinks PROG Holdings’ Stock is Going to Recover
- EF Hutton Thinks Odyssey Marine Exploration’s Stock is Going to Recover
- Wedbush Thinks Customers Bancorp’s Stock is Going to Recover
